Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 4Carcinoma, Squamous Cell 2Loco-regional Esophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Radiotherapy 11Cisplatin 10Paclitaxel 9pembrolizumab 7Fluorouracil 7Oxaliplatin 6Irinotecan 6tislelizumab 5Cetuximab 5Docetaxel 4Radiation 3Nivolumab 3Leucovorin 3Carboplatin 3Capecitabine 3Neoadjuvant Therapy 2Immunohistochemistry 2Biopsy 210-propargyl-10-deazaaminopterin 2tremelimumab 1sitravatinib 1sintilimab 1regorafenib 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1oblimersen 1durvalumab 1cixutumumab 1adavosertib 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Squamous Cell Carcinoma × Esophagectomy × Clear all
NCT03223662 2018-10-30

Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 6 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡